Table 1 Previous reports of t-AML development in HLH patients treated with etoposide
Author and year of publication | Patient age (yr)/sex at onset of HLH | Disease as described | Etoposide cumulative doses prior to t-AML (mg/m2) | Additional anti-tumor agents for HLH | Time (mo) of t-AML from HLH therapy | Chromosome karyotype | The type of leukemia | Treatment for t-AML and outcome |
|---|---|---|---|---|---|---|---|---|
Rama Chandran and Ariffin 2009 [7] | 1.4/M | EBV-HLH | 4800 | Intrathecal MTX | 36 | t(15;17) (q22;q12) | M3 | chemotherapy, alive |
Kitazawa et al. 2001 [10] | 4/F | EBV-HLH | 3150 | None | 31 | Normal | M2 | Die after allo-HSCT |
Takahashi et al. 1998 [11] | 19/F | VAHS | 900 | Ara C | 32 | t(9;11) (p22;q23) | M4 | Died after allo-HSCT |
Rama Chandran and Ariffin 2011 [7] | 1.5/M | VAHS | 6150 | Intrathecal MTX | 48 | t(15;17) (q21;q22) | M3 | chemotherapy, alive |
Rama Chandran and Ariffin 2011 [7] | 3.5/F | VAHS | 1200 | none | 24 | Normal | M5 | On chemotherapy, alive |
Stine et al. 1997 [13] | 11/M | VAHS | 3100 | Intrathecal MTX | 26 | t(9;11) (p22;q23) | M4 | Died after allo-HSCT |
Henter et al. 1993 [15] | 3/M | FHL | 20,500 | Vm-26 3400 mg/m2, Intrathecal MTX | 72 | normal karyotype | MDS | Allo-HSCT, alive |
Shamsian BS et al. 2010 [8] | 12/F | HLH | 400 | MTX, prednisone, mercaptopurine | 24 | Normal | T-ALL | chemotherapy, die |
Rudd et al. 2006 [16] | 0.3/F | FHL | 3150 | None | 24 | t(15;17) | M3 | chemotherapy, alive |
Su et al. 2013 [5] | 0.66/F | EBV-HLH | 3520 | None | 18 | t(15;17) (q22;q12) | M3 | On chemotherapy, alive. |
Seo et al. 2007 [9] | 62/F | VAHS | 300 | None | 31 | Normal | M5 | On chemotherapy, alive. |
Ng et al. 2004 [12] | 1.5/M | EBV-HLH | 1350 | None | 6 | t(9;11) (p22;q23) | AML | Allo-HSCT, alive |
Ohtake et al. 2006 [14] | 2/M | EBV-HLH | 3900 | None | 14 | t(9;11) (p22;q23) | AML | Allo-HSCT, alive |